<!DOCTYPE html >
<html lang="en">
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p178" style="overflow: hidden; position: relative; background-color: white; width: 433px; height: 649px;">

<!-- Begin shared CSS values -->
<style class="shared-css" type="text/css" >
.t {
	-webkit-transform-origin: top left;
	-moz-transform-origin: top left;
	-o-transform-origin: top left;
	-ms-transform-origin: top left;
	-webkit-transform: scale(0.25);
	-moz-transform: scale(0.25);
	-o-transform: scale(0.25);
	-ms-transform: scale(0.25);
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
}
</style>
<!-- End shared CSS values -->


<!-- Begin inline CSS -->
<style type="text/css" >

#t1_178{left:4px;top:233px;letter-spacing:-0.1px;}
#t2_178{left:4px;top:78px;letter-spacing:-0.3px;}
#t3_178{left:5px;top:629px;letter-spacing:-1.8px;}
#t4_178{left:52px;top:40px;letter-spacing:-1px;}
#t5_178{left:59px;top:40px;letter-spacing:-1px;word-spacing:1.3px;}
#t6_178{left:174px;top:40px;letter-spacing:-1px;word-spacing:1.3px;}
#t7_178{left:59px;top:56px;letter-spacing:-1px;word-spacing:1.2px;}
#t8_178{left:59px;top:71px;letter-spacing:-1px;word-spacing:4.8px;}
#t9_178{left:59px;top:86px;letter-spacing:-0.9px;word-spacing:-1.3px;}
#ta_178{left:59px;top:101px;letter-spacing:-1px;word-spacing:-0.1px;}
#tb_178{left:43px;top:136px;letter-spacing:-1px;word-spacing:-0.3px;}
#tc_178{left:43px;top:154px;letter-spacing:-1px;word-spacing:3.7px;}
#td_178{left:43px;top:169px;letter-spacing:-1px;word-spacing:-1.2px;}
#te_178{left:43px;top:184px;letter-spacing:-1px;word-spacing:0.5px;}
#tf_178{left:43px;top:200px;letter-spacing:-0.9px;word-spacing:-0.1px;}
#tg_178{left:48px;top:223px;}
#th_178{left:317px;top:223px;}
#ti_178{left:48px;top:238px;}
#tj_178{left:102px;top:239px;}
#tk_178{left:327px;top:238px;}
#tl_178{left:48px;top:254px;}
#tm_178{left:48px;top:266px;}
#tn_178{left:327px;top:260px;}
#to_178{left:48px;top:282px;}
#tp_178{left:327px;top:282px;}
#tq_178{left:48px;top:297px;}
#tr_178{left:128px;top:298px;}
#ts_178{left:327px;top:297px;}
#tt_178{left:48px;top:313px;}
#tu_178{left:327px;top:313px;}
#tv_178{left:48px;top:328px;}
#tw_178{left:327px;top:328px;}
#tx_178{left:48px;top:344px;}
#ty_178{left:327px;top:344px;}
#tz_178{left:48px;top:359px;}
#t10_178{left:48px;top:372px;}
#t11_178{left:327px;top:365px;}
#t12_178{left:48px;top:387px;}
#t13_178{left:327px;top:387px;}
#t14_178{left:48px;top:403px;}
#t15_178{left:327px;top:403px;}
#t16_178{left:48px;top:418px;}
#t17_178{left:327px;top:418px;}
#t18_178{left:43px;top:440px;}
#t19_178{left:45px;top:440px;letter-spacing:0.9px;word-spacing:0.2px;}
#t1a_178{left:43px;top:450px;letter-spacing:0.6px;word-spacing:-0.4px;}
#t1b_178{left:89px;top:451px;}
#t1c_178{left:91px;top:450px;letter-spacing:0.8px;word-spacing:-0.8px;}
#t1d_178{left:43px;top:461px;letter-spacing:0.8px;word-spacing:-0.6px;}
#t1e_178{left:43px;top:485px;letter-spacing:-1px;word-spacing:4.2px;}
#t1f_178{left:43px;top:500px;letter-spacing:-1px;}
#t1g_178{left:43px;top:517px;letter-spacing:-1px;word-spacing:-0.1px;}
#t1h_178{left:43px;top:552px;letter-spacing:-1px;word-spacing:-0.4px;}
#t1i_178{left:141px;top:552px;letter-spacing:-0.9px;word-spacing:-0.3px;}
#t1j_178{left:43px;top:568px;letter-spacing:-1px;}
#t1k_178{left:271px;top:568px;letter-spacing:-1px;}
#t1l_178{left:333px;top:568px;letter-spacing:-0.8px;}
#t1m_178{left:43px;top:583px;letter-spacing:-0.9px;word-spacing:-0.3px;}
#t1n_178{left:79px;top:583px;letter-spacing:-1px;}
#t1o_178{left:138px;top:583px;letter-spacing:-1px;word-spacing:-0.1px;}

.s1_178{
	FONT-SIZE: 48.9px;
	FONT-FAMILY: AllerDisplay_lq;
	color: rgb(156,100,158);
}

.s2_178{
	FONT-SIZE: 48.9px;
	FONT-FAMILY: AllerDisplay_lq;
	color: rgb(35,31,32);
}

.s3_178{
	FONT-SIZE: 39.7px;
	FONT-FAMILY: AllerDisplay_lq;
	color: rgb(255,255,255);
}

.s4_178{
	FONT-SIZE: 48.9px;
	FONT-FAMILY: Helvetica-Condensed-Bold_j0;
	color: rgb(35,31,32);
}

.s5_178{
	FONT-SIZE: 48.9px;
	FONT-FAMILY: Helvetica-Condensed_ix;
	color: rgb(35,31,32);
}

.s6_178{
	FONT-SIZE: 36.7px;
	FONT-FAMILY: Helvetica-Condensed-Bold_j0;
	color: rgb(35,31,32);
}

.s7_178{
	FONT-SIZE: 36.7px;
	FONT-FAMILY: Helvetica-Condensed_ix;
	color: rgb(35,31,32);
}

.s8_178{
	FONT-SIZE: 21.4px;
	FONT-FAMILY: Helvetica-Condensed_ix;
	color: rgb(35,31,32);
}

.s9_178{
	FONT-SIZE: 17.8px;
	FONT-FAMILY: Helvetica-Condensed_ix;
	color: rgb(35,31,32);
}

.s10_178{
	FONT-SIZE: 30.6px;
	FONT-FAMILY: Helvetica-Condensed_ix;
	color: rgb(35,31,32);
}

.t.m0_178{
	-webkit-transform: matrix(0,-1,1,0,0, 0) scale(0.25);
	-ms-transform: matrix(0,-1,1,0,0, 0) scale(0.25);
	-moz-transform: matrix(0,-1,1,0,0, 0) scale(0.25);
	-o-transform: matrix(0,-1,1,0,0, 0) scale(0.25);
}

</style>
<!-- End inline CSS -->

<!-- Begin embedded font definitions -->
<style id="fonts178" type="text/css" >

@font-face {
	font-family: Helvetica-Condensed-Bold_j0;
	src: url("fonts/Helvetica-Condensed-Bold_j0.woff") format("woff");
}

@font-face {
	font-family: AllerDisplay_lq;
	src: url("fonts/AllerDisplay_lq.woff") format("woff");
}

@font-face {
	font-family: Helvetica-Condensed_ix;
	src: url("fonts/Helvetica-Condensed_ix.woff") format("woff");
}

</style>
<!-- End embedded font definitions -->

<!-- Begin page background -->
<div id="pg178Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg178" style="-webkit-user-select: none;"><object width="433" height="649" data="178/178.svg" type="image/svg+xml" id="pdf178" style="width:433px; height:649px; -moz-transform:scale(1); z-index: 0;"></object></div>
<!-- End page background -->


<!-- Begin text definitions (Positioned/styled in CSS) -->
<div id="t1_178" class="t m0_178 s1_178">O Guia do Jovem Internista </div>
<div id="t2_178" class="t m0_178 s2_178">2016</div>
<div id="t3_178" class="t s3_178">176</div>
<div id="t4_178" class="t s4_178">- </div>
<div id="t5_178" class="t s4_178">Anticoagulantes diretos</div>
<div id="t6_178" class="t s5_178">- inibidores específicos dos fatores II (Da-</div>
<div id="t7_178" class="t s5_178">bigatrano) ou Xa ((Rivaroxabano, Apixabano, Edoxabano), com ad-</div>
<div id="t8_178" class="t s5_178">ministração oral, dose fixa, sem necessidade de controlo. Usados </div>
<div id="t9_178" class="t s5_178">na prevenção e tratamento do TEV e na FA não valvular. Apresentam </div>
<div id="ta_178" class="t s5_178">algumas interações pelos CYP3A4 e glicoproteína-P.</div>
<div id="tb_178" class="t s4_178">• Anticoagulação profilática</div>
<div id="tc_178" class="t s5_178">A decisão de anticoagulação profilática deve ser feita de forma indivi-</div>
<div id="td_178" class="t s5_178">dualizada, tendo em conta os fatores de risco trombóticos e hemorrági-</div>
<div id="te_178" class="t s5_178">cos dos doentes. A escala de Padua é uma ferramenta útil na avaliação </div>
<div id="tf_178" class="t s5_178">de risco trombótico, em doentes médicos: </div>
<div id="tg_178" class="t s6_178">Fator de Risco</div>
<div id="th_178" class="t s7_178">Pontos</div>
<div id="ti_178" class="t s7_178">Neoplasia ativa</div>
<div id="tj_178" class="t s8_178">a</div>
<div id="tk_178" class="t s7_178">3</div>
<div id="tl_178" class="t s7_178">Tromboembolismo venoso prévio (não inclui tromboflebite </div>
<div id="tm_178" class="t s7_178">superficial)</div>
<div id="tn_178" class="t s7_178">3</div>
<div id="to_178" class="t s7_178">Mobilidade reduzida</div>
<div id="tp_178" class="t s7_178">3</div>
<div id="tq_178" class="t s7_178">Trombofilia conhecida</div>
<div id="tr_178" class="t s8_178">b</div>
<div id="ts_178" class="t s7_178">3</div>
<div id="tt_178" class="t s7_178">Trauma ou cirurgia recentes (último mês)</div>
<div id="tu_178" class="t s7_178">2</div>
<div id="tv_178" class="t s7_178">Idade avançada (&gt; 70 anos)</div>
<div id="tw_178" class="t s7_178">1</div>
<div id="tx_178" class="t s7_178">Insuficiência cardíaca ou doença respiratório</div>
<div id="ty_178" class="t s7_178">1</div>
<div id="tz_178" class="t s7_178">Enfarte agudo do miocárdio ou acidente vascular cerebral is-</div>
<div id="t10_178" class="t s7_178">quémico</div>
<div id="t11_178" class="t s7_178">1</div>
<div id="t12_178" class="t s7_178">Infeção aguda ou doença reumatológica</div>
<div id="t13_178" class="t s7_178">1</div>
<div id="t14_178" class="t s7_178">Obesidade (IMC &gt; 30Kg/m2) </div>
<div id="t15_178" class="t s7_178">1</div>
<div id="t16_178" class="t s7_178">Hormonoterapia</div>
<div id="t17_178" class="t s7_178">1</div>
<div id="t18_178" class="t s9_178">a</div>
<div id="t19_178" class="t s10_178">doentes com metastização local/à distância, ou submetidos a quimioterapia ou radioterapia nos últi-</div>
<div id="t1a_178" class="t s10_178">mos 6 meses; </div>
<div id="t1b_178" class="t s9_178">b</div>
<div id="t1c_178" class="t s10_178">portadores de alterações da antitrombina, proteínas C ou S, fator V de Leiden, mutação </div>
<div id="t1d_178" class="t s10_178">G20210A da protrombina ou síndrome dos anticorpos antifosfolípidos</div>
<div id="t1e_178" class="t s5_178">Um score superior ou igual a 4 identifica doentes de alto risco trom-</div>
<div id="t1f_178" class="t s5_178">bótico.</div>
<div id="t1g_178" class="t s5_178">As opções de anticoagulação profilática passam por:</div>
<div id="t1h_178" class="t s4_178">HBPM: Enoxaparina</div>
<div id="t1i_178" class="t s5_178">40mg/d sc 1xd (nos doentes com obesidade grau </div>
<div id="t1j_178" class="t s5_178">3 poderão ser necessários doses mais elevadas); </div>
<div id="t1k_178" class="t s4_178">Nadroparina</div>
<div id="t1l_178" class="t s5_178">0,3ml/d </div>
<div id="t1m_178" class="t s5_178">sc 1xd; </div>
<div id="t1n_178" class="t s4_178">Dalteparina</div>
<div id="t1o_178" class="t s5_178">5000 UI/d sc 1xd;</div>

<!-- End text definitions -->


</div>
</body>
</html>
